{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:42Z","timestamp":1793137002958,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Social Science & Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.socscimed.2026.119668","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:11:42Z","timestamp":1785856302000},"page":"119668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Political and organizational influences in the side effects of FDA approved drugs"],"prefix":"10.1016","volume":"408","author":[{"given":"Jason","family":"Schnittker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.socscimed.2026.119668_bib1","series-title":"Fixed Effects Regression Methods for Longitudinal Data Using SAS","year":"2005"},{"key":"10.1016\/j.socscimed.2026.119668_bib2","series-title":"Alfred A. Knopf.","article-title":"Powerful medicines: the benefits, risks, and costs of prescription drugs","author":"Avorn","year":"2004"},{"issue":"27","key":"10.1016\/j.socscimed.2026.119668_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe2030687","article-title":"The FDA and the importance of trust","volume":"383","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.socscimed.2026.119668_bib4","series-title":"Agendas and Instability in American Politics","author":"Baumgartner","year":"1993"},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib5","first-page":"24","article-title":"Frances Oldham Kelsey. FDA medical reviewer leaves her mark on history","volume":"35","author":"Bren","year":"2001","journal-title":"FDA Consum."},{"issue":"9","key":"10.1016\/j.socscimed.2026.119668_bib6","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1377\/hlthaff.2020.00284","article-title":"Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990-2015","volume":"39","author":"Buxbaum","year":"2020","journal-title":"Health Aff."},{"issue":"3","key":"10.1016\/j.socscimed.2026.119668_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jleo\/ewp002","article-title":"Early entrant protection in approval regulation: theory and evidence from FDA drug review","volume":"26","author":"Carpenter","year":"2010","journal-title":"J. Law Econ. Organ."},{"issue":"1","key":"10.1016\/j.socscimed.2026.119668_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1377\/hlthaff.23.1.52","article-title":"The political economy of FDA drug review: processing, politics, and lessons for policy","volume":"23","author":"Carpenter","year":"2004","journal-title":"Health Aff."},{"key":"10.1016\/j.socscimed.2026.119668_bib9","series-title":"Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA","author":"Carpenter","year":"2014"},{"issue":"14","key":"10.1016\/j.socscimed.2026.119668_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.polisci.032408.171344","article-title":"The politics of regulation: from new institutionalism to new governance","volume":"14","author":"Carrigan","year":"2011","journal-title":"Annu. Rev. Polit. Sci."},{"issue":"6","key":"10.1016\/j.socscimed.2026.119668_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJMra1907805","article-title":"Placebo and nocebo effects","volume":"382","author":"Colloca","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.socscimed.2026.119668_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11186-015-9247-6","article-title":"Unintended but not unanticipated consequences","volume":"44","author":"de Zwart","year":"2015","journal-title":"Theor. Soc."},{"key":"10.1016\/j.socscimed.2026.119668_bib13","series-title":"Congress and the Administrative State","author":"Dodd","year":"1986"},{"issue":"1","key":"10.1016\/j.socscimed.2026.119668_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/lsq.12323","article-title":"Problem solving and the demand for expert information in congress","volume":"47","author":"Fagan","year":"2022","journal-title":"Legis. Stud. Q."},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cpt.3292","article-title":"Trust in the food and drug administration: a national survey study","volume":"116","author":"Feldman","year":"2024","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41591-020-01200-w","article-title":"The limits of acceptable political influence over the FDA","volume":"27","author":"Fernandez Lynch","year":"2021","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hast.990","article-title":"Federal right to try: where is it going?","volume":"49","author":"Folkers","year":"2019","journal-title":"Hastings Cent. Rep."},{"key":"10.1016\/j.socscimed.2026.119668_bib18","series-title":"Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products","year":"1998"},{"key":"10.1016\/j.socscimed.2026.119668_bib19","series-title":"Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making, Draft PDUFA V Implementation Plan, Fiscal Years 2013-2017","year":"2013"},{"issue":"1","key":"10.1016\/j.socscimed.2026.119668_bib20","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1038\/s41467-020-18305-y","article-title":"Predicting the frequencies of drug side effects","volume":"11","author":"Galeano","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.socscimed.2026.119668_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1191\/0960327105ht517oa","article-title":"Evidence-based toxicology: a comprehensive framework for causation","volume":"24","author":"Guzelian","year":"2005","journal-title":"Hum. Exp. Toxicol."},{"issue":"4","key":"10.1016\/j.socscimed.2026.119668_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1468-0009.00223","article-title":"Trust in physicians and medical institutions: what is It, can it be measured, and does it matter?","volume":"79","author":"Hall","year":"2001","journal-title":"Milbank Q."},{"issue":"6","key":"10.1016\/j.socscimed.2026.119668_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/virtualmentor.2012.14.6.pfor2-1206","article-title":"Antidepressants and the FDA's black-box warning: determining a rational public policy in the absence of sufficient evidence","volume":"14","author":"Ho","year":"2012","journal-title":"AMA Journal of Ethics"},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib24","first-page":"431","article-title":"The state of science at the Food and Drug Administration","volume":"60","author":"Hutt","year":"2008","journal-title":"Adm. Law Rev."},{"key":"10.1016\/j.socscimed.2026.119668_bib25","series-title":"The Textbook of Pharmaceutical Medicine","first-page":"461","article-title":"The regulation of drug products by the US Food and Drug Administration","author":"Hutt","year":"2013"},{"key":"10.1016\/j.socscimed.2026.119668_bib26","series-title":"Food and Drug Administration Advisory Committees","year":"1992"},{"issue":"19","key":"10.1016\/j.socscimed.2026.119668_bib27","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse events in randomized trials: neglected, restricted, distorted, and silenced","volume":"169","author":"Ioannidis","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.socscimed.2026.119668_bib28","series-title":"Policy Agendas Project: Codebook","author":"Jones","year":"2023"},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib29","first-page":"55","article-title":"FDA and clinical drug trials: a short history","volume":"2008","author":"Junod","year":"2008","journal-title":"FDLI Update"},{"key":"10.1016\/j.socscimed.2026.119668_bib30","article-title":"Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study","volume":"351","author":"Kesselheim","year":"2015","journal-title":"BMJ"},{"issue":"D1","key":"10.1016\/j.socscimed.2026.119668_bib31","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.socscimed.2026.119668_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1057\/s41292-022-00293-5","article-title":"Epistemology of the side effect: anecdote and evidence in the digital age","volume":"19","author":"Lentacker","year":"2024","journal-title":"BioSocieties"},{"issue":"21","key":"10.1016\/j.socscimed.2026.119668_bib33","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/archinternmed.2012.4444","article-title":"New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010?","volume":"172","author":"Lexchin","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib34","first-page":"65","article-title":"How safe and innovative are first-in-class drugs approved by Health Canada: a cohort study","volume":"12","author":"Lexchin","year":"2016","journal-title":"Healthc. Policy"},{"issue":"582","key":"10.1016\/j.socscimed.2026.119668_bib35","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3399\/bjgp11X548910","article-title":"Ascertaining the size of the symptom iceberg in a UK-wide community-based survey","volume":"61","author":"McAteer","year":"2011","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.socscimed.2026.119668_bib36","series-title":"On Social Structure and Science","author":"Merton","year":"1996"},{"issue":"1","key":"10.1016\/j.socscimed.2026.119668_bib37","article-title":"Examining the nocebo effect of statins through statin adverse events reported in the Food and Drug Administration adverse event reporting system","volume":"14","author":"Moon","year":"2021","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1016\/j.socscimed.2026.119668_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pmedr.2014.08.002","article-title":"Safety vs. efficacy assessment of pharmaceuticals: epistemological rationales and methods","volume":"1","author":"Osimani","year":"2014","journal-title":"Prev. Med. Rep."},{"issue":"9","key":"10.1016\/j.socscimed.2026.119668_bib39","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1176\/appi.ajp.161.9.1692","article-title":"Safety reporting in randomized trials of mental health interventions","volume":"161","author":"Papanikolaou","year":"2004","journal-title":"Am. J. Psychiatr."},{"issue":"19","key":"10.1016\/j.socscimed.2026.119668_bib40","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch. Intern. Med."},{"issue":"22","key":"10.1016\/j.socscimed.2026.119668_bib41","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1001\/jama.2018.6741","article-title":"Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States","volume":"319","author":"Qato","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.socscimed.2026.119668_bib42","series-title":"Vital Statistics on Congress","author":"Reynolds","year":"2024"},{"issue":"2","key":"10.1016\/j.socscimed.2026.119668_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archinte.166.2.155","article-title":"Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects","volume":"166","author":"Rief","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.socscimed.2026.119668_bib44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/pds.2067","article-title":"Assessing general side effects in clinical trials: reference data from the general population","volume":"20","author":"Rief","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.socscimed.2026.119668_bib45","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/bmj.p1061","article-title":"The decline of science at the FDA has become unmanageable","volume":"381","author":"Ross","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.socscimed.2026.119668_bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cels.2016.03.001","article-title":"Metabolic network prediction of drug side effects","volume":"2","author":"Shaked","year":"2016","journal-title":"Cell Syst."},{"issue":"3","key":"10.1016\/j.socscimed.2026.119668_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0003055404001285","article-title":"Regulatory regimes, agency actions, and the conditional nature of congressional influence","volume":"98","author":"Shipan","year":"2004","journal-title":"Am. Polit. Sci. Rev."},{"issue":"7470","key":"10.1016\/j.socscimed.2026.119668_bib48","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bmj.329.7470.816-a","article-title":"Merck withdraws arthritis drug worldwide","volume":"329","author":"Singh","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.socscimed.2026.119668_bib49","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1146\/annurev-clinpsy-050212-185533","article-title":"Drug approval and drug effectiveness","volume":"10","author":"Spielmans","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"6","key":"10.1016\/j.socscimed.2026.119668_bib50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.socscimed.2026.119668_bib51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","article-title":"Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC, Basic Transl. Sci."},{"issue":"5","key":"10.1016\/j.socscimed.2026.119668_bib52","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1016\/j.sapharm.2021.06.009","article-title":"History, status, and politicization of the FDA","volume":"18","author":"Wang","year":"2022","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"53","key":"10.1016\/j.socscimed.2026.119668_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-pharmtox-011112-140159","article-title":"One hundred years of drug regulation: where do we go from here?","volume":"53","author":"Woosley","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.socscimed.2026.119668_bib54","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.socscimed.2026.119668_bib55","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4088\/JCP.08m04978blu","article-title":"Underrecognition of clinically significant side effects in depressed outpatients","volume":"71","author":"Zimmerman","year":"2010","journal-title":"J. Clin. Psychiatr."}],"container-title":["Social Science & Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0277953626007458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0277953626007458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:31:35Z","timestamp":1793136695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0277953626007458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"alternative-id":["S0277953626007458"],"URL":"https:\/\/doi.org\/10.1016\/j.socscimed.2026.119668","relation":{},"ISSN":["0277-9536"],"issn-type":[{"value":"0277-9536","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Political and organizational influences in the side effects of FDA approved drugs","name":"articletitle","label":"Article Title"},{"value":"Social Science & Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.socscimed.2026.119668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"119668"}}